Clinical trial
Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated…
NCT00327223 · AmpliMed Corporation, Industry · Completed
Key facts
| NCT number | NCT00327223 |
|---|---|
| Title | Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy |
| Official title | A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Administered Daily for 5 Days Every 3 Weeks to Patients With Metastatic Cancer or Disseminated Malignancy |
| Lead sponsor | AmpliMed Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | imexon |
| Enrollment | 18 |
| Start date | Nov 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | May 18, 2006 |
| Last update posted | Mar 14, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: